INTELLIGENCE TICKER

Drug Approval→ORIG· 1 min agoClinical Trial Initiation→Navidea Biopharmaceuticals Inc· 21h agoDrug Approval→Memorial Sloan-kettering Cancer Center Rdrc· 21h agoClinical Trial Termination→Infinityltl Engineered Compounds· 4d agoCDMO Deal→Merck Receives EC· 4d agoDrug Approval→ORIG· 1 min agoClinical Trial Initiation→Navidea Biopharmaceuticals Inc· 21h agoDrug Approval→Memorial Sloan-kettering Cancer Center Rdrc· 21h agoClinical Trial Termination→Infinityltl Engineered Compounds· 4d agoCDMO Deal→Merck Receives EC· 4d ago

ChemLifeIntel Terminal

Chemical & Life Sciences Intelligence

Decision-grade regulatory, trade and market signals across 65,000+ entities — built for procurement, regulatory-affairs and market-intelligence teams in pharma and chemicals.

COVERAGE

ENTITIES

ANALYST ON CALL

Priya Subramaniam

Intelligence Analyst

Generic Markets ·Patent Strategy

Currently covering:

AbbVie Secures FDA Approval for RINVOQ LQ (Upadacitinib) Oral Solution: Strategic Expansion with Orphan Designation

View All Coverage

UPCOMING DEADLINES

NEXT 30 DAYS

JUL

USFDA

Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugate…

AUG

USFDA

Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar E…

AUG

USFDA

Forms FDA 3542a and FDA 3542: Questions and Answers

AUG

USTR

Initiation of Second Four-Year Review Process: China's Acts, Policies, and Practices Related…

AUG

USFDA

Master Protocols for Drug and Biological Product Development

LATEST INTELLIGENCE BRIEFS

47 new today

CLINICAL & PIPELINE·Drug Approval

AbbVie Secures FDA Approval for RINVOQ LQ (Upadacitinib) Oral Solution: Strategic Expansion with Orphan Designation

AbbVie has secured FDA approval for RINVOQ LQ (Upadacitinib) 1MG/ML oral solution, a new dosage form for its existing Janus Kinase Inhibitor. This Type 3 submission, with Orphan Drug designation, was approved on April 26, 2024, expanding patient access and market opportunities for Upadacitinib, particularly for those needing liquid formulations.

90-Day Activity

ORIG

PSPriya Subramaniam· Intelligence Analyst

1 min ago

CLINICAL & PIPELINE·Clinical Trial Initiation

Duboce Biopharmaceuticals Initiates Phase 1a/1b Clinical Trial for Novel Biologic DBC-664 in Advanced Solid Tumors

Duboce Biopharmaceuticals, Inc. has commenced a Phase 1a/1b clinical trial (NCT07705035) for its novel biologic, DBC-664, targeting advanced solid tumors. This first-in-human study, recruiting 210 patients, will assess safety, pharmacokinetics, and preliminary anti-tumor activity. This move signals Duboce's strategic entry into the competitive oncology market, impacting future development and partnership opportunities for stakeholders.

90-Day Activity

Navidea Biopharmaceuticals DBC-664

AIAnanya Iyer· Principal Intelligence Analyst

21h ago

CLINICAL & PIPELINE·Drug Approval

Memorial Sloan Kettering Completes Phase 2 BMT Trial for Genetic Blood Disorders

Memorial Sloan Kettering Cancer Center has completed a Phase 2 clinical trial (NCT00578435) on allogeneic bone marrow transplantation for severe genetic erythropoiesis disorders. This comprehensive study, concluded in 2008, evaluated BMT's role in treating sickle cell anemia, thalassemia, and Diamond Blackfan anemia, utilizing specific conditioning and prophylaxis regimens. Its findings inform future therapeutic development and supply chain strategies for critical BMT pharmaceuticals.

90-Day Activity

Memorial Sloan-kettering Cancer Center Rdrc

AIAnanya Iyer· Principal Intelligence Analyst

21h ago

CLINICAL & PIPELINE·Clinical Trial Termination

Infinity Pharmaceuticals' IPI-504 Phase 2 Trial for ALK-Positive NSCLC Terminated Due to Slow Accrual

Infinity Pharmaceuticals, Inc. faces a strategic setback with the termination of its Phase 2 clinical trial (NCT01228435) for IPI-504, an Hsp90 inhibitor, in ALK-positive NSCLC patients. The trial, led by Massachusetts General Hospital, ceased due to slow accrual, having enrolled only three participants. This event impacts future R&D investments and competitive positioning in targeted oncology therapies.

90-Day Activity

Infinityltl Engineered Compounds IPI-504

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

4d ago Clinical Trial Termination

MARKET INTELLIGENCE·CDMO Deal

Merck's Alimatravir Licensing Reshapes HIV PrEP Market Access Ahead of Regulatory Approval

Merck's voluntary licensing of alimatravir for HIV PrEP, preceding regulatory submissions, signals a proactive market access strategy mirroring Gilead. This move impacts global supply chains by diversifying manufacturing potential and accelerates patient access. Procurement directors must prepare for multi-source API strategies, while regulatory affairs heads should anticipate complex, staggered approvals and market entry. Business development executives should evaluate this model for pipeline assets.

90-Day Activity

Merck Receives EC alimatravir

RARobert Ashworth· Principal Intelligence Analyst

4d ago CDMO Deal

CLINICAL & PIPELINE·Clinical Trial Update

Mayo Clinic Advances Diffuse Midline Glioma Treatment with Phase 2 SPORT-DMG Radiation Trial

Mayo Clinic has initiated a Phase 2 clinical trial (NCT05077735) for hypofractionated radiation therapy in Diffuse Midline Glioma, H3 K27M-Mutant. This SPORT-DMG trial aims to assess a shorter, 2-week radiation course against the standard 6-week regimen, targeting improved 10-month overall survival and patient quality of life. This development signals potential shifts in oncology treatment protocols for this aggressive brain cancer.

90-Day Activity

People's Custom Rx And Clinical Care, LLC

AIAnanya Iyer· Principal Intelligence Analyst

4d ago Clinical Trial Update

CLINICAL & PIPELINE·Clinical Trial Completion

Aurion Biotech Completes Phase 1 Clinical Trial for HCEC-1 in Corneal Edema

Aurion Biotech has completed its Phase 1 clinical trial (NCT05309135) for HCEC-1, a novel human corneal endothelial cell therapy combined with Rho kinase inhibitor Y-27632, targeting corneal edema secondary to endothelial dysfunction. This milestone de-risks early-stage development, paving the way for potential advancement into later clinical phases and signaling a significant step in regenerative ophthalmic treatments.

90-Day Activity

Aurion Biotech

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

4d ago

REGULATORY INTELLIGENCE·FDA Action

FDA Advisory Committee Recommends Restoring Four Peptide Drugs to 503A List, Boosting Compounding Capacity

The FDA's Pharmacy Compounding Advisory Committee has recommended restoring four peptide drugs to the 503A Bulk Drug Substances list. This crucial decision removes prior production limits for compounders, signaling enhanced market access and operational flexibility. For procurement directors and supply chain VPs, this action could alleviate specific supply pressures and diversify sourcing options for these critical therapies in the United States.

90-Day Activity

FDA AMINOBUTYROYL TRIPEPTIDE-1HSN 3004.90

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

4d ago▲ Trending signal

CLINICAL & PIPELINE·Drug Approval

FDA Advisory Panel Recommends Expanded Compounding Access for Peptides BPC-157, KPV, TB-500, and MOTS-c

The FDA's advisory panel recommended allowing compounding pharmacies to manufacture BPC-157, KPV, TB-500, and MOTS-c. This non-binding vote, influenced by peptide industry ties, signals potential for significantly expanded market access for these unapproved substances. Decision-makers must prepare for increased demand for these APIs and evolving regulatory oversight in the US market.

90-Day Activity

FDA

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

5d ago Drug Approval

CLINICAL & PIPELINE·Drug Approval

Eli Lilly's Retatrutide Filing Signals Intensified Obesity Market Competition and Supply Chain Pressures

Eli Lilly is set to file for FDA approval of its triple-agonist retatrutide in Q1 2027, intensifying competition in the rapidly expanding obesity market. This move, following strong Phase 3 data, highlights significant supply chain and manufacturing demands. Procurement and regulatory teams must monitor Lilly's capacity and market shifts closely.

90-Day Activity

Eli Lilly Retatrutide

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

5d ago Drug Approval

CLINICAL & PIPELINE·Drug Approval

GSK's Jideytro FDA Approval Bolsters Oncology Portfolio After $10.6B Nuvalent Acquisition

GSK secured FDA approval for Jideytro (zidesamtinib) for ROS1-positive metastatic NSCLC, a key return on its $10.6 billion Nuvalent acquisition. This approval accelerates GSK's oncology expansion, positioning Jideytro as a next-generation therapy in a competitive but underserved market, with significant implications for procurement and market access strategies.

90-Day Activity

GSK Jideytro

AIAnanya Iyer· Principal Intelligence Analyst

6d ago Drug Approval

CLINICAL & PIPELINE·Phase 3 Completion

Summit Therapeutics Bolsters Ivonescimab's FDA Case with Updated Phase 3 Survival Data

Summit Therapeutics has strategically released updated overall survival data from its Phase 3 HARMONi trial for ivonescimab, a PD-1xVEGF bispecific antibody. This move aims to bolster the drug's profile ahead of a critical FDA decision, signaling a proactive regulatory approach. Decision-makers should monitor this development closely for its implications on future oncology treatment landscapes and potential supply chain shifts in the United States.

90-Day Activity

Summit Industries ivonescimab

LVLakshmi Venkataraman· Senior Intelligence Analyst

6d ago▲ Trending signal

TRADE & SUPPLY CHAIN·Trade Flow

U.S. Generic Drug Tariffs: 100-200% Levies Threaten Supply Chains and Mandate Reshoring by 2028

President Trump's threat of 100% tariffs on U.S. generic drug imports by August 2028, escalating to 200%, signals a critical trade flow shift aimed at reshoring production. This policy, despite Supreme Court limitations on unilateral action, poses significant risks to generic drugmakers' narrow profit margins, potentially leading to product discontinuations, shortages, and quality compromises. Decision-makers must urgently re-evaluate supply chain resilience and explore domestic manufacturing investments.

90-Day Activity

Jubilant Generics LimitedHSN 3004

PSPriya Subramaniam· Intelligence Analyst

6d ago Trade Flow

TRADE & SUPPLY CHAIN·Trade Flow

U.S. Tariff Threat on Indian Generics: Navigating 100-200% Levies and Supply Chain Disruption

The United States plans to impose tariffs of 100% to 200% on imported generic medicines from India starting August 2028. This aggressive trade policy, targeting the largest source of U.S. generics, threatens to significantly raise costs, trigger drug shortages, and necessitate urgent re-evaluation of global pharmaceutical supply chains for procurement directors and supply chain VPs.

90-Day Activity

Korea United Pharmaceuticals

PSPriya Subramaniam· Intelligence Analyst

6d ago Trade Flow

CLINICAL & PIPELINE·Drug Approval

University of Massachusetts Completes Pivotal MST-EA Trial for Antisocial Behavior in Emerging Adults

The University of Massachusetts, Worcester, has completed a pivotal clinical trial (NCT02922335) for Multisystemic Therapy-Emerging Adults (MST-EA). This behavioral intervention targets serious antisocial behavior in emerging adults with mental illness, addressing a critical unmet public health need. The completion signals a potential shift in evidence-based mental health service delivery for high-risk populations, impacting future procurement and policy.

90-Day Activity

Curia Massachusetts,

PSPriya Subramaniam· Intelligence Analyst

6d ago

CLINICAL & PIPELINE·Clinical Trial

Sun Yat-sen University Advances Anlotinib in Phase 4 Head and Neck Cancer Trial (NCT04507035)

Sun Yat-sen University is conducting a Phase 4 clinical trial (NCT04507035) evaluating Anlotinib hydrochloride capsules combined with chemoradiotherapy for locally advanced head and neck cancer. This study, led by Principal Investigator Zhen-Wei Peng, targets improved survival and tumor regression in refractory cases. For procurement and business development, this highlights emerging treatment paradigms and potential market shifts in oncology.

90-Day Activity

China Pharmaceutical University Doxycycline HydrochlorideHSN 3004.90.90

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

6d ago

MARKET INTELLIGENCE·CDMO Deal

Crystalys Therapeutics Secures $130 Million Series B to Advance Dotinurad for Global Gout Market Entry

Crystalys Therapeutics secured $130 million in Series B financing to accelerate late-stage development and launch preparations for dotinurad, a URAT1 inhibitor for gout. This capital infusion positions Crystalys to challenge existing therapies and creates significant opportunities for CDMOs and supply chain partners preparing for a new entrant in the global gout market.

90-Day Activity

Crystalys Therapeutics Dotinurad

JWJames Whitfield· Senior Intelligence Analyst

6d ago CDMO Deal

MARKET INTELLIGENCE·M&A

Amgen Settles Investor Lawsuit for $74 Million Over Alleged $10.7 Billion Hidden Tax Liability

Amgen has agreed to a $74 million settlement with investors, resolving claims it concealed a $10.7 billion tax bill, artificially inflating its share price from July 2020 to April 2022. This financial outlay underscores the critical importance of transparent financial reporting for biotech firms, impacting investor confidence and demanding heightened due diligence from procurement and regulatory leaders.

90-Day Activity

Amgen Filgrastim Amgen, Inc. · Thousand OaksHSN 30049099HSN 29339900HSN 29372900

RARobert Ashworth· Principal Intelligence Analyst

7d ago▲ Trending signal

CLINICAL & PIPELINE·Phase 3 Completion

Agios Pharmaceuticals Halts Tebapivat Development for Sickle Cell Disease Amidst Mid-Stage Trial Disappointment

Agios Pharmaceuticals has halted mid-stage development of tebapivat for sickle cell disease due to insufficient differentiation, impacting its competitive position against Novo Nordisk. This setback elevates the commercial importance of Agios's mitapivat, which holds US FDA Priority Review for sickle cell with an approval decision expected by November 1. Procurement and supply chain leaders must monitor the volatile sickle cell market.

90-Day Activity

Agios Pharmaceuticals tebapivat

LVLakshmi Venkataraman· Senior Intelligence Analyst

7d ago Phase 3 Completion

CLINICAL & PIPELINE·Clinical Trial Initiation

QHSLab Initiates Pivotal Clinical Trial (NCT06603935) for Digital Allergic Rhinitis Management Platform

QHSLab, Inc. has initiated a pivotal clinical trial (NCT06603935) for its digital medicine platform, integrating Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) to enhance allergic rhinitis control in primary care. This 12-month, randomized study targets 240 adults, evaluating symptom severity, adherence, and economic impact, signaling a strategic move in digital health for chronic condition management.

90-Day Activity

QHSLab,

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

7d ago

REGULATORY INTELLIGENCE·Warning Letter

FDA Issues Warning Letter to Alembic Pharmaceuticals, Signaling Heightened Regulatory Scrutiny

Alembic Pharmaceuticals, a key Indian generics producer, has received an FDA Warning Letter following a prior Form 483. This escalates regulatory risk for their Vadodara operations, potentially impacting supply continuity for multiple generic molecules. Procurement and regulatory teams must assess exposure and monitor remediation closely to mitigate disruption.

90-Day Activity

Alembic Pharmaceuticals

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

7d ago Warning Letter

CLINICAL & PIPELINE·Clinical Trial Termination

Hoffmann-La Roche Halts Idasanutlin Phase Ib/II Trial for Acute Myeloid Leukemia Due to Strategic Re-prioritization

Hoffmann-La Roche has terminated its Phase Ib/II clinical trial (NCT03850535) for Idasanutlin in Acute Myeloid Leukemia (AML). This decision, effective June 2022, was driven by an 'overall company strategy about the adult AML' rather than safety concerns. This signals a significant re-prioritization within Roche's oncology pipeline, impacting future development and API procurement for Idasanutlin.

90-Day Activity

Hoffmann La Roche Idasanutlin F. Hoffmann - La Roche Ltd. · Kaiseraugst

AIAnanya Iyer· Principal Intelligence Analyst

7d ago▲ Trending signal

CLINICAL & PIPELINE·Drug Approval

Medical University of Vienna Completes Pivotal Observational Study on Heavy Metals, Angiogenesis, and CAD (NCT02159235)

The Medical University of Vienna has completed its observational study (NCT02159235) investigating heavy metals, angiogenesis factors, and osteopontin in Coronary Artery Disease. This research provides critical insights for cardiovascular diagnostics and environmental health, identifying correlations between metal levels and disease severity. For procurement and R&D, these findings underscore the need for advanced biomarker detection and potential new targets for therapeutic development, influencing future research and diagnostic tool investments.

90-Day Activity

China Pharmaceutical UniversityHSN 3822.00HSN 9027.80

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

7d ago

CLINICAL & PIPELINE·Phase 3 Completion

Merck and Gilead's Islatravir/Lenacapavir Phase 3 Success Reshapes HIV Treatment Landscape with Once-Weekly Regimen

Merck and Gilead's Islatravir/Lenacapavir combination has completed Phase 3 trials, demonstrating efficacy matching daily HIV treatments like Biktarvy. This once-weekly, single-tablet regimen represents a significant advancement in HIV viral suppression, promising enhanced patient adherence and a substantial shift in the competitive landscape for procurement directors and business development executives in the global life sciences industry.

90-Day Activity

LVLakshmi Venkataraman· Senior Intelligence Analyst

7d ago Phase 3 Completion

MARKET INTELLIGENCE·M&A

Novo Nordisk Challenges Eli Lilly's GLP-1 Marketing Claims, Intensifying Diabetes and Obesity Market Competition

Novo Nordisk has initiated a legal dispute against Eli Lilly, alleging "deliberately false" advertising regarding the comparative efficacy of GLP-1 medicines. This action underscores the fierce competition in the diabetes and obesity markets, impacting procurement strategies and regulatory compliance for global chemical and life sciences firms. This dispute could reshape marketing standards for blockbuster drugs like Semaglutide.

90-Day Activity

Novo Nordisk SemaglutideHSN 29339900

RARobert Ashworth· Principal Intelligence Analyst

7d ago M&A

MARKET INTELLIGENCE·M&A

Tempus Acquires Personalis for $1.5 Billion, Bolstering Position in Blood-Based Cancer Diagnostics

Tempus's $1.5 billion acquisition of Personalis significantly strengthens its foothold in the rapidly expanding blood-based cancer diagnostics market. This strategic move reflects growing medtech interest in less invasive testing, impacting procurement strategies, regulatory pathways, and competitive dynamics across the global oncology sector. Decision-makers must assess portfolio shifts and supply chain implications.

90-Day Activity

Tempus Sangivamycin Hcl As Prepared By The Frederick Cancer ResHSN 3822.00.00

RARobert Ashworth· Principal Intelligence Analyst

8d ago M&A

MARKET INTELLIGENCE·CDMO Deal

Samsung Biologics' $1.8 Billion PolyPeptide Acquisition Reshapes Peptide CDMO Landscape for Weight Loss Market

Samsung Biologics' $1.8 billion acquisition of Switzerland-based PolyPeptide marks a significant strategic pivot into peptide production and the booming weight loss market. This move diversifies Samsung's CDMO capabilities beyond biologics, offering new supply chain options and intensifying competition for procurement directors and business development executives in this high-growth therapeutic area.

90-Day Activity

Samsung Biologics Samsung Biologics Co., Ltd. · Yeonsu DistrictHSN 30049099

RARobert Ashworth· Principal Intelligence Analyst

8d ago CDMO Deal

MARKET INTELLIGENCE·Product Launch

Legend Biotech's 10% Stock Drop Signals Deeper Concerns Despite Record Carvykti Sales

Legend Biotech experienced a 10% stock drop despite partner Johnson & Johnson reporting record sales for their CAR-T therapy, Carvykti, in multiple myeloma. This market reaction, triggered by J&J's earnings call comments, signals investor concerns beyond immediate revenue. Decision-makers must scrutinize partnership communication and supply chain perceptions in advanced therapy commercialization.

90-Day Activity

Biolegend Carvykti

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

8d ago Product Launch

CLINICAL & PIPELINE·Drug Approval

Merck's Lipfendra Secures FDA Approval as First Oral PCSK9 Inhibitor, Unlocking $5 Billion Hypercholesterolemia Market

Merck's Lipfendra has received FDA approval on July 16, 2026, marking the first oral PCSK9 inhibitor for hypercholesterolemia. This approval creates a significant commercial opportunity, with market potential estimated at $5 billion, profoundly impacting cardiovascular treatment paradigms. Procurement and supply chain leaders must evaluate new sourcing strategies for this oral formulation, while regulatory and business development teams will navigate evolving market access dynamics.

90-Day Activity

Merck Receives EC

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

8d ago Drug Approval

CLINICAL & PIPELINE·Clinical Study Registration

Peking University Cancer Hospital Initiates Multi-omics ESCC Study (NCT07152535): Strategic Implications for Oncology Development

Peking University Cancer Hospital & Institute has registered a prospective observational multi-omics study (NCT07152535) for Esophageal Squamous Cell Carcinoma (ESCC). This initiative, focusing on dynamic disease evolution and biomarker discovery, signals significant opportunities for diagnostic developers, contract research organizations, and pharmaceutical firms in precision oncology, particularly within the Chinese market.

90-Day Activity

China Pharmaceutical University

AIAnanya Iyer· Principal Intelligence Analyst

8d ago

CLINICAL & PIPELINE·Drug Approval

Dr. Falk Pharma GmbH Concludes Pivotal Phase III Trial for Budesonide in Eosinophilic Esophagitis

Dr. Falk Pharma GmbH has completed its pivotal Phase III clinical trial (NCT02493335) for Budesonide Orodispersible Tablets in Eosinophilic Esophagitis. This milestone positions the company for potential regulatory filings, offering a specialized treatment option for adult EoE patients. Procurement directors and regulatory heads should monitor the data release and subsequent market entry, which could reshape treatment paradigms and market access strategies for this chronic condition.

90-Day Activity

Dr. Falk Pharma GmbH BudesonideHSN 2937.22.00

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

8d ago

CLINICAL & PIPELINE·Clinical Trial Completion

Cairo University Completes Clinical Study NCT05579535 on Gait Intervention for Pediatric Spastic Diplegia

Cairo University has completed clinical study NCT05579535, investigating the effect of ankle weights on hip excursion in children with spastic diplegia. This interventional study, led by Nahla Mohamed Ibrahim, provides critical data for non-pharmacological approaches in pediatric neurological rehabilitation. Decision-makers should monitor results for potential impacts on physical therapy protocols and rehabilitation product development.

90-Day Activity

China Pharmaceutical University

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

8d ago

CLINICAL & PIPELINE·Drug Approval

Kaligia Biosciences Initiates Clinical Study for Non-Invasive Glucose Monitoring Devices in Diabetes Management

Kaligia Biosciences, LLC, in collaboration with Florida Hospital Tampa Bay Division, has initiated a clinical study (NCT03607435) for its KBS-1 non-invasive and RBA-1 minimally invasive glucose monitoring devices. This study aims to calibrate performance data against standard methods, signaling a potential shift in diabetes diagnostics. Decision-makers should monitor this development for future market entry and procurement implications in diabetes care.

90-Day Activity

Gufic Biosciences Limited

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

11d ago

CLINICAL & PIPELINE·Drug Approval

Tianjin Medical University Cancer Institute Advances Phase III Trial for Biliary Tract Cancer Adjuvant Therapy

Tianjin Medical University Cancer Institute and Hospital is advancing a Phase III clinical trial (NCT03779035) evaluating adjuvant Gemcitabine plus Capecitabine versus Capecitabine alone for biliary tract cancer after curative resection. This study targets improved disease-free survival in cholangiocarcinoma and gallbladder carcinoma, potentially reshaping postoperative treatment protocols. Procurement and R&D teams should monitor this trial's progress for future market shifts in oncology therapeutics.

90-Day Activity

China Pharmaceutical University

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

11d ago

CLINICAL & PIPELINE·Clinical Trial Update

Singapore Trial Explores AI-Driven Nivolumab and Pembrolizumab Dose Optimization in Solid Tumors

National University Hospital, Singapore, is advancing a Phase 1/2 clinical trial (NCT05175235) for Nivolumab and Pembrolizumab dose optimization in solid tumors using the CURATE.AI platform. This study, collaborating with Natera, Inc., aims to personalize immunotherapy dosing via AI and ctDNA measurements, potentially reducing the significant semi-annual treatment costs of approximately $140,000 per patient in the United States while maximizing clinical outcomes.

90-Day Activity

NivolumabHSN Not applicable from source

AIAnanya Iyer· Principal Intelligence Analyst

11d ago

REGULATORY INTELLIGENCE·Form 483

FDA Issues Form 483s to Manufacturing Sites in Indiana and Iceland, Signaling Heightened Scrutiny

The FDA has issued Form 483 observations to manufacturing sites in Indiana and Iceland, underscoring persistent regulatory challenges for facilities with prior compliance issues. This signals intensified scrutiny from the FDA, necessitating immediate action from procurement and supply chain leaders to assess supplier risk and ensure robust quality systems.

90-Day Activity

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

11d ago Form 483

CLINICAL & PIPELINE·Drug Approval

Novartis Secures Full FDA Approval for Fabhalta in IgA Nephropathy, Bolstering Renal Portfolio

Novartis has achieved full FDA approval for Fabhalta in IgA nephropathy, marking a critical milestone for patients at risk of kidney function decline. This transition from accelerated approval solidifies Fabhalta's market position, demanding robust supply chain scaling and strategic commercial planning from Novartis Pharmaceutical Corp to meet anticipated demand and ensure broad patient access.

90-Day Activity

Novartis FabhaltaHSN 3004.90

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

11d ago Drug Approval

MARKET INTELLIGENCE·M&A

Jasper Therapeutics Acquires Kira Pharmaceuticals, Expanding Immune Drug Pipeline and Securing $132M Lifeline

Jasper Therapeutics has acquired Kira Pharmaceuticals in an all-stock deal, securing a $132 million private offering to fund operations through H2 2028. This merger provides Jasper a critical lifeline, diversifying its pipeline with Kira's promising complement system inhibitors, KP-104 and KP-701, for rare immune and kidney diseases. This strategic move aims to revitalize Jasper's market position after prior setbacks, impacting competitive dynamics in PNH and IgA nephropathy.

90-Day Activity

Jasper Therapeutics briquilimab

RARobert Ashworth· Principal Intelligence Analyst

11d ago M&A

TRADE & SUPPLY CHAIN·Molecule Spotlight

mRNA LNP Patent Wars Escalate: Arbutus, Sanofi Challenge Pfizer, Moderna; New Therapies Advance

Arbutus and Sanofi are escalating mRNA lipid nanoparticle (LNP) patent disputes against Pfizer, BioNTech, and Moderna across the U.S., Europe, and Canada, impacting market access and IP strategies. Concurrently, InnoCare's soficitinib and Insmed's TPIP show promising clinical trial results, while Argenx and Chai Discovery forge AI-driven antibody discovery partnerships, signaling shifts in R&D investment and future therapeutic pipelines.

90-Day Activity

Arbutus

ASArjun Sharma· Senior Intelligence Analyst

11d ago Molecule Spotlight

CLINICAL & PIPELINE·Clinical Trial Termination

Fate Therapeutics Terminates Phase 1 FT538 Trial for Advanced Solid Tumors: Strategic Implications for NK-Cell Immunotherapy

Fate Therapeutics has terminated its Phase 1 clinical trial (NCT05069935) for FT538, an allogeneic NK-cell immunotherapy targeting advanced solid tumors. This sponsor-initiated decision, effective September 2023, impacts the development of novel oncology treatments. Procurement and business development teams should reassess Fate Therapeutics' pipeline and monitor the broader NK-cell therapy landscape for strategic adjustments and emerging opportunities.

90-Day Activity

Fate Therapeutics

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

11d ago

CLINICAL & PIPELINE·Phase 3 Completion

Positive Phase 3 ADC Readouts by Kelun-Biotech and Hansoh Pharma Reshape Oncology Market Dynamics

Kelun-Biotech (Merck) and Hansoh Pharma (GSK) announced positive Phase 3 readouts for their Antibody-Drug Conjugates (ADCs) in oncology. This signals significant market shifts and intensified competition in targeted cancer therapies. Procurement directors and supply chain VPs must prepare for increased demand for specialized ADC manufacturing components and expertise, while business development executives should evaluate new partnership opportunities.

90-Day Activity

Sichuan Kelun Pharmaceutical

LVLakshmi Venkataraman· Senior Intelligence Analyst

11d ago Phase 3 Completion

CLINICAL & PIPELINE·Phase 3 Completion

GSK Shelves $2 Billion Camlipixant Chronic Cough Drug After Phase 3 Failure, Reshaping Market Dynamics

GSK has discontinued camlipixant's Phase 3 trials for chronic cough, shelving a drug acquired in a $2 billion deal. This failure, the third for a P2X3 antagonist, creates an 'open field opportunity' for Trevi Therapeutics' Haduvio, prompting a significant shift in the competitive landscape for respiratory treatments and re-emphasizing GSK's oncology focus.

90-Day Activity

GSK camlipixant

AIAnanya Iyer· Principal Intelligence Analyst

11d ago Phase 3 Completion

MARKET INTELLIGENCE·M&A

Eli Lilly's $2.8 Billion AtaiBeckley Acquisition Validates Psychedelics for Depression, Reshaping Neuroscience Market

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, with an initial $2.8 billion equity value, marks a pivotal moment for psychedelic-based therapies. This strategic move diversifies Lilly's neuroscience portfolio, spearheaded by BPL-003 for treatment-resistant depression. It signals major pharmaceutical validation, compelling procurement and business development leaders to re-evaluate emerging drug pipelines and market access strategies in this rapidly evolving sector.

90-Day Activity

Eli Lilly BPL-003

RARobert Ashworth· Principal Intelligence Analyst

12d ago M&A

CLINICAL & PIPELINE·Clinical Trial Completion

Retina Research Foundation Completes Phase I/II Study for Ranibizumab (Lucentis) in Macular Degeneration

Retina Research Foundation completed a Phase I/II study (NCT00467935) for ranibizumab (Lucentis) in advanced wet Macular Degeneration. This trial investigated scotoma reduction and improved visual function in 20 patients, concluding in November 2007. The findings contribute to the understanding of anti-VEGF therapies for AMD, informing future R&D strategies and procurement decisions for ophthalmic treatments, highlighting ongoing innovation in this critical therapeutic area.

90-Day Activity

Henry M. Jackson Foundation for the Advancement of Military Medicine LucentisHSN 3002.15

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

12d ago

CLINICAL & PIPELINE·Phase 2 Success

Veradermics' VDPHL01 Phase 2 Success Signals Major Shift in Female Pattern Hair Loss Treatment

Veradermics' VDPHL01, an oral extended-release minoxidil, demonstrated significant Phase 2 success in female pattern hair loss, exceeding investor expectations with a 23 hairs/cm² increase. This de-risks its ongoing Phase 3 program, signaling a potential first-in-class oral treatment for women. Procurement and supply chain leaders should assess future minoxidil API demand and monitor competitive innovations in the rapidly evolving hair loss market.

90-Day Activity

Veradermics VDPHL01HSN 3004.90.90.90

LVLakshmi Venkataraman· Senior Intelligence Analyst

12d ago Phase 2 Success

CLINICAL & PIPELINE·Drug Approval

Merck's Lipfendra: First Oral PCSK9 Inhibitor Reshapes Hypercholesterolemia Market with $5 Billion Potential

Merck's FDA approval of Lipfendra, the first oral PCSK9 inhibitor for hypercholesterolemia, marks a significant shift in cardiovascular treatment. With a projected peak annual sales potential of $5 billion, this approval presents substantial commercial and supply chain opportunities for Merck, demanding robust manufacturing and strategic market access planning to capitalize on its novel oral formulation.

90-Day Activity

Merck Receives EC Lipfendra

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

12d ago Drug Approval

CLINICAL & PIPELINE·Drug Approval

NPO Petrovax Concludes Pivotal Phase 3 Trial for Polyoxidonium in Pediatric Acute Respiratory Infections

NPO Petrovax has completed its pivotal Phase 3 clinical trial (NCT03840135) for Polyoxidonium nasal and sublingual spray, 6 mg/ml, targeting Acute Respiratory Infections (ARI) in children aged 1-12 years. This development signals potential market entry for a non-FDA regulated treatment, requiring procurement and regulatory teams to assess its commercial viability and regional regulatory pathways, particularly for pediatric ARI management.

90-Day Activity

Polyoxidonium

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

12d ago

CLINICAL & PIPELINE·Drug Approval

Ionis Pharmaceuticals Completes Phase 2a Clinical Trial for IONIS-FB-LRx in Primary IgA Nephropathy

Ionis Pharmaceuticals, Inc. has completed its Phase 2a clinical study (NCT04014335) of IONIS-FB-LRx for primary IgA Nephropathy. This antisense inhibitor targets complement factor B, a crucial pathway in kidney disease. The trial, enrolling 23 participants across multiple countries, evaluated effectiveness and safety, marking a key milestone in the development of this novel therapeutic for a significant unmet medical need.

90-Day Activity

Ionisos IONIS-FB-LRx

PSPriya Subramaniam· Intelligence Analyst

12d ago

CLINICAL & PIPELINE·Drug Approval

UCSF Suspends Phase 1 Clinical Trial for Zr-89 Cimzia PET Imaging in Rheumatoid Arthritis Due to Funding Lapse

The University of California, San Francisco (UCSF) has suspended its Phase 1 clinical trial (NCT03546335) for Zr-89 Cimzia PET imaging in rheumatoid arthritis, citing a lapse in study funding. This halt impacts the development of a novel diagnostic radiopharmaceutical, raising concerns for stakeholders in medical imaging, autoimmune disease diagnostics, and radiopharmaceutical supply chains regarding investment and pipeline stability.

90-Day Activity

Zr-89 Cimzia

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

12d ago

CLINICAL & PIPELINE·Drug Approval

Masonic Cancer Center Completes Phase 2 Trial for Hematological Diseases, Refining Transplant Regimens

The Masonic Cancer Center, University of Minnesota, completed its Phase 2 trial (NCT02661035) for hematological diseases. This study refined allogeneic hematopoietic stem cell transplantation (HSCT) using reduced intensity conditioning with cyclophosphamide, fludarabine, tacrolimus, and mycophenolate mofetil. This provides critical data on GVHD rates, influencing future transplant protocols and pharmaceutical procurement strategies for these established agents.

90-Day Activity

China Pharmaceutical University

AIAnanya Iyer· Principal Intelligence Analyst

12d ago

CLINICAL & PIPELINE·Drug Approval

Merck's Oral PCSK9 Inhibitor Lipfendra Gains FDA Approval, Reshaping Hypercholesterolemia Market Dynamics

Merck & Co.'s Lipfendra (enlicitide), the first oral PCSK9 inhibitor, received FDA approval on July 16, 2026, for high cholesterol. This approval, potentially expedited by a controversial voucher program, introduces a competitively priced alternative to injectables, crucial for Merck's post-Keytruda growth strategy. Procurement and market access teams must assess its impact on formulary strategies and patient adherence.

90-Day Activity

Merck & Co Lipfendra

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

12d ago Drug Approval

MARKET INTELLIGENCE·Capacity Update

Merck's Oral PCSK9 Approval, Eli Lilly's Psychedelics Acquisition, and New Prediction Markets Signal Major Biopharma Market Shifts

Recent market activities signal significant strategic shifts for global chemical and life sciences. Merck's oral PCSK9 drug FDA approval redefines cardiovascular treatment, impacting procurement and R&D. Eli Lilly's acquisition of Atai expands its therapeutic footprint into psychedelics, while Kalshi's new prediction markets for clinical trials introduce novel risk assessment tools, collectively reshaping investment and supply chain strategies across the biopharma sector.

90-Day Activity

United States Trade Representatives

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

12d ago Capacity Update

CLINICAL & PIPELINE·Drug Approval

Merck's Keytruda Secures First-in-Class Front-Line Approval for Endometrial Cancer Subtype, Reshaping Treatment Paradigm

Merck & Co.'s Keytruda is now the first PD-1 inhibitor approved as a single agent for front-line treatment of a specific endometrial cancer subtype. This expands Keytruda's market dominance, demanding supply chain adjustments and strategic re-evaluation by competitors. It signifies a critical shift in oncology treatment paradigms.

90-Day Activity

Merck & Co Keytruda

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

13d ago Drug Approval

REGULATORY INTELLIGENCE·Settlement

Glenmark Pharmaceuticals Settles $29.6 Million Price-Fixing Allegations with States, Signaling Heightened Generic Market Scrutiny

Glenmark Pharmaceuticals Inc USA has agreed to pay $29.6 million to settle multi-state price-fixing allegations concerning generic medicines. This resolution underscores persistent regulatory scrutiny on generic drug pricing, impacting procurement strategies and supply chain risk assessments for companies relying on generic manufacturers. Decision-makers must evaluate supplier compliance and market stability.

90-Day Activity

Glenmark Pharmaceuticals Limited

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

13d ago Settlement

CLINICAL & PIPELINE·Drug Approval

Celcuity's Revtorpyk Gains FDA Approval for ER+/HER2- Breast Cancer, Faces Launch Delays and Market Scrutiny

Celcuity secured FDA approval for Revtorpyk, a critical second-line treatment for ER-positive, HER2-negative breast cancer patients without PIK3CA mutations. Despite this milestone, Celcuity's shares fell nearly 20% due to an unexpected launch delay to late Q3 2026 and higher-than-anticipated discontinuation rates in the prescribing information, prompting close market observation for this new entrant.

90-Day Activity

Celcuity Revtorpyk

PSPriya Subramaniam· Intelligence Analyst

13d ago Drug Approval

CLINICAL & PIPELINE·Phase 3 Completion

Kelun-Biotech's Sac-TMT Phase 3 Success in China Signals Major Shift for PD-L1-Low NSCLC Treatment

Kelun-Biotech, partnered with Merck, announced positive Phase 3 results for sac-TMT in China for PD-L1-low non-squamous NSCLC. This antibody-drug conjugate demonstrated superior progression-free survival against chemotherapy, marking a critical advance for a challenging patient population. This validates Merck's significant ADC investment and signals a potential shift in front-line lung cancer treatment standards, impacting procurement and supply chain strategies globally.

90-Day Activity

Sichuan Kelun Pharmaceutical sac-TMT

LVLakshmi Venkataraman· Senior Intelligence Analyst

13d ago Phase 3 Completion

MARKET INTELLIGENCE·Market Entry

Attovia Therapeutics and Braveheart Bio IPOs Signal Robust Biotech Funding for Immunology and Cardiology

Attovia Therapeutics and Braveheart Bio are pursuing IPOs, leveraging strong biotech market momentum. Attovia focuses on immunology and dermatology with ATTO-1310, ATTO-2306, and ATTO-1091. Braveheart targets hypertrophic cardiomyopathy with BHB‑1893, licensed from Hengrui Pharma. These market entries highlight significant capital availability for innovative drug development, impacting competitive landscapes and future supply chain demands in specialized therapeutic areas.

90-Day Activity

Braveheart

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

13d ago Market Entry

MARKET INTELLIGENCE·CDMO Deal

Insilico Medicine's $2.5 Billion Bora Pharmaceuticals Deal Signals Escalating AI Impact on CDMO Market

Insilico Medicine, a generative AI specialist, has partnered with CDMO Bora Pharmaceuticals in a collaboration potentially valued at $2.5 billion in milestones. This deal underscores the escalating integration of AI in drug discovery and development, signaling significant shifts for procurement, supply chain, and regulatory functions. For CDMOs, securing such high-value, AI-driven partnerships is critical for future growth and market relevance.

90-Day Activity

Insilico Medicine

RARobert Ashworth· Principal Intelligence Analyst

13d ago CDMO Deal

REGULATORY INTELLIGENCE·Warning Letter

FTC Settlement Mandates CVS Caremark Insulin Pricing Reforms, Projecting Billions in Patient Savings

The Federal Trade Commission settled a lawsuit against CVS Caremark over allegations of insulin price manipulation. This landmark agreement mandates significant changes to CVS Caremark's dealings with health plans and pharmacies, aiming to save Americans up to $13 billion in insulin costs over the next decade. This signals intensified regulatory scrutiny on Pharmacy Benefit Manager (PBM) rebate practices.

90-Day Activity

Cvs Caremark Insulin

PSPriya Subramaniam· Intelligence Analyst

14d ago Warning Letter

CLINICAL & PIPELINE·Clinical Study Completion

Xinhua Hospital Completes Pivotal Clinical Study (NCT03515135) on Non-Pharmacological ADHD Intervention for Preschoolers

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, has completed a randomized controlled study (NCT03515135) for Metacognitive Executive Function Training (MEFP) in preschool children with ADHD. This non-pharmacological intervention, targeting 4-6 year olds, aims to provide an early treatment alternative to psychostimulants, which are noted for controversial efficacy and side effects in this demographic. This completion signals a potential shift in early ADHD management strategies.

90-Day Activity

China Pharmaceutical University

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

14d ago

Loading more intelligence…